NYSE:ELN

E559465

NYSE:ELN was the stock ticker symbol for Elan Pharmaceuticals, an Irish biotechnology company known for developing treatments for neurological and autoimmune diseases.

All labels observed (1)

Label Occurrences
NYSE:ELN canonical 2

How this entity was disambiguated

Statements (47)

Predicate Object
instanceOf biotechnology company ⓘ
public company ⓘ
acquiredBy Perrigo Company plc ⓘ
linked to: Perrigo
acquisitionDate 2013 ⓘ
acquisitionValue approximately $8.6 billion ⓘ
collaboratedWith Biogen Idec ⓘ
linked to: Biogen

Johnson & Johnson ⓘ
Wyeth ⓘ
countryOfOrigin Ireland ⓘ
currencyOfStock GBP ⓘ
linked to: Pound sterling

USD ⓘ
delistedFrom LSE ⓘ
NYSE ⓘ
developedFor Alzheimer's disease ⓘ
Crohn's disease ⓘ
multiple sclerosis ⓘ
focusesOn autoimmune diseases ⓘ
neurological diseases ⓘ
formerTicker LSE:ELA ⓘ
NYSE:ELN ⓘ
foundedBy Don Panoz ⓘ
foundedIn 1969 ⓘ
headquartersLocation Dublin, Ireland ⓘ
linked to: Dublin
industry biotechnology ⓘ
pharmaceuticals ⓘ
ISIN IE0003072950 ⓘ
legalIssue accounting and financial reporting investigations in early 2000s ⓘ
listedOn LSE ⓘ
NYSE ⓘ
notableEvent Tysabri safety concerns and temporary market withdrawal in 2005 ⓘ
reintroduction of Tysabri with risk management program ⓘ
notableMarket Europe ⓘ
United States ⓘ
notableProduct Antegren ⓘ
Bapineuzumab ⓘ
linked to: bapineuzumab

Tysabri ⓘ
primaryTherapeuticArea immunology ⓘ
neurology ⓘ
reasonForDelisting acquisition by Perrigo ⓘ
researchFocus biologic therapies ⓘ
central nervous system disorders ⓘ
monoclonal antibodies ⓘ
status defunct as independent company ⓘ
stockExchange London Stock Exchange ⓘ
New York Stock Exchange ⓘ
tradedAs LSE:ELA ⓘ
NYSE:ELN ⓘ

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

Elan Pharmaceuticals → tradedAs → NYSE:ELN ⓘ
Elan Corporation plc → formerTicker → NYSE:ELN ⓘ
subject linked to: NYSE:ELN